# HAVCR2 (TIM-3): Galectin-9 Binding, Exhausted T-Cell Signaling, and Tumor Microenvironment Suppressor


## Key Takeaways

- HAVCR2 (TIM-3) is an immune checkpoint receptor that binds galectin-9 (LGALS9) and other ligands, suppressing effector T-cell function and promoting T-cell exhaustion.
- Germline loss-of-function mutations in HAVCR2 are causally linked to subcutaneous panniculitis-like T-cell lymphoma (SPTCL) with hemophagocytic lymphohistiocytosis (HLH), highlighting its role as a tumor suppressor in specific contexts.
- TIM-3 is a validated therapeutic target in oncology, with monoclonal antibodies like sabatolimab in clinical trials for hematologic and solid malignancies, aiming to reverse T-cell exhaustion within the tumor microenvironment.
- Beyond T cells, TIM-3 modulates innate immune cells like dendritic cells and macrophages, influencing inflammasome activity, efferocytosis, and cytokine secretion, thereby shaping the tumor immune landscape.
- The cytoplasmic tail of TIM-3 orchestrates a signaling switch from BAT3-mediated T-cell activation to SHP-2-mediated T-cell inhibition upon ligand engagement, a critical mechanism for immune tolerance and exhaustion.
- TIM-3 expression is dysregulated in chronic viral infections (e.g., HIV, HBV) and neurodegenerative diseases (e.g., Alzheimer's), contributing to immune dysfunction and disease progression.

---

## Executive Summary & Key Metadata

Hepatitis A Virus Cellular Receptor 2 (HAVCR2), most widely recognized by its protein product T-cell Immunoglobulin and Mucin-domain containing-3 (TIM-3), is a type I transmembrane glycoprotein belonging to the TIM family of immune checkpoint receptors. Since its initial discovery in 2002 as a molecule selectively expressed on interferon-gamma (IFN-γ)-producing CD4+ Th1 and CD8+ cytotoxic T cells, TIM-3 has emerged as a central regulator of immune tolerance, T-cell exhaustion, and innate immune quiescence. The gene encodes a receptor that, upon engagement with its principal soluble ligand galectin-9 (LGALS9), triggers a cascade of intracellular signaling events that suppress effector T-cell function, promote the differentiation of regulatory T cells, and drive the functional exhaustion of tumor-infiltrating lymphocytes (TILs). Beyond its canonical role in adaptive immunity, HAVCR2 is expressed on innate immune cells—including dendritic cells (DCs), natural killer (NK) cells, and macrophages—where it modulates inflammasome activity, efferocytosis, and cytokine secretion.

The clinical relevance of HAVCR2 spans a broad spectrum of pathologies. In oncology, TIM-3 is a validated target for checkpoint blockade immunotherapy, with multiple monoclonal antibodies (e.g., sabatolimab) in clinical trials for hematologic and solid malignancies. Conversely, germline loss-of-function mutations in HAVCR2 are causally linked to subcutaneous panniculitis-like T-cell lymphoma (SPTCL) with hemophagocytic lymphohistiocytosis (HLH), as well as recurrent autoinflammatory myocarditis, highlighting the receptor's dual role as both a tumor suppressor in specific lymphomas and a pro-tumorigenic immune checkpoint in the tumor microenvironment (TME). This manual provides a comprehensive, biophysically detailed reference on the genomic architecture, structural biology, signaling networks, pathogenic mutations, and therapeutic targeting of HAVCR2.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | HAVCR2 |
| UniProt Accession | Q8TDQ0 |
| Representative PDB ID | 6NGI |
| Chromosomal Locus | 5q33.3 |
| Primary Molecular Function | Immune checkpoint receptor; binds LGALS9, HMGB1, CEACAM1, and phosphatidylserine; suppresses Th1/Th17 and CD8+ T-cell effector function; induces T-cell exhaustion |
| Disease & Pathology Associations | Subcutaneous panniculitis-like T-cell lymphoma (SPTCL), hemophagocytic lymphohistiocytosis (HLH), recurrent autoinflammatory myocarditis, chronic viral infections (HIV, HBV, EBV), solid tumors (melanoma, NSCLC, HCC, ovarian, gastric), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic obstructive pulmonary disease (COPD), Alzheimer's disease |
| Primary Ligand | Galectin-9 (LGALS9) |
| Other Ligands | HMGB1, CEACAM1, Phosphatidylserine (PtdSer) |
| Expression Pattern | Activated/exhausted CD4+ Th1, CD8+ T cells, Tregs, NK cells, DCs, macrophages, microglia, mast cells |
| Therapeutic Antibodies | Sabatolimab (MBG453), Cobolimab (TSR-022), LY3321367, Sym023 |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The HAVCR2 gene is located on the long arm of chromosome 5 at cytogenetic band 5q33.3. This region is a well-established immunoregulatory hotspot, containing a cluster of genes encoding other TIM family members (HAVCR1/TIM-1, TIMD4/TIM-4) as well as the genes for IL-4, IL-13, and CSF2 (GM-CSF). The precise genomic coordinates (GRCh38/hg38) span approximately 25.5 kilobases (kb) from 156,509,276 to 156,534,789 on the forward strand. The gene comprises seven exons and six introns, with the translational start site located in exon 1 and the stop codon in exon 7. The mature mRNA transcript is approximately 2.1 kb in length, with a 5' untranslated region (UTR) of ~200 nucleotides and a 3' UTR of ~1.1 kb that contains multiple AU-rich elements (AREs) and microRNA (miRNA) binding sites critical for post-transcriptional regulation.

### 1.2 Promoter Architecture and Transcriptional Regulation

The core promoter of HAVCR2 lacks a canonical TATA box but contains a high-density CpG island spanning the proximal promoter and exon 1, making the gene susceptible to epigenetic silencing via DNA methylation. DNase I hypersensitivity mapping and chromatin immunoprecipitation (ChIP) experiments have identified several critical transcription factor (TF) binding sites within a 2 kb region upstream of the transcription start site (TSS). Key transcriptional regulators include:

- **NFATc1 and NFATc2**: Nuclear factor of activated T-cells (NFAT) family members bind to the proximal promoter and are essential for the initial activation-induced expression of HAVCR2 following T-cell receptor (TCR) engagement. NFATc2 has been specifically implicated in driving the expression of exhaustion-associated genes, including HAVCR2, in chronically stimulated CD8+ T cells.
- **TOX and TOX2**: Thymocyte selection-associated high mobility group box (TOX) proteins are master regulators of T-cell exhaustion. TOX2 directly binds to the HAVCR2 promoter and upregulates TIM-3 transcription in T-cell acute lymphoblastic leukemia (T-ALL) and exhausted T cells. Notably, nuclear-cytosolic translocation of TOX2 leads to loss of TIM3 transcription, linking subcellular localization of this TF to HAVCR2 expression.
- **NFIL3**: Nuclear factor, interleukin 3 regulated (NFIL3/E4BP4) is a basic leucine zipper (bZIP) TF that binds to the HAVCR2 promoter and drives TIM-3 expression in effector Th1 cells, contributing to inflammation in chronic obstructive pulmonary disease (COPD).
- **PRDM1 (Blimp-1)**: In prostate cancer, PRDM1 has been shown to drive a TIM3+ macrophage immunosuppressive niche, likely through direct or indirect transcriptional activation of HAVCR2.
- **RAR/RXR heterodimers**: Retinoic acid receptors have been implicated in modulating HAVCR2 expression in myeloid cells.

### 1.3 Enhancer Elements and 3D Chromatin Architecture

High-throughput chromatin conformation capture (Hi-C) and enhancer RNA (eRNA) profiling have revealed that HAVCR2 is regulated by multiple distal enhancer elements located up to 100 kb upstream and downstream of the TSS. A critical enhancer region, located approximately 8 kb upstream of the TSS, contains a binding site for the transcription factor AP-1 and is required for maximal inducible expression in activated T cells. A functional single nucleotide polymorphism (SNP) within this enhancer, rs13360222 (T allele), has been demonstrated to decrease enhancer activity in a cell model of human macrophages, leading to reduced HAVCR2 expression. This finding underscores the importance of non-coding regulatory variation in modulating TIM-3 levels and, consequently, immune checkpoint function.

CRISPR-based functional annotation of the enhancer landscape in primary human T cells has identified several additional regulatory elements that control HAVCR2 expression, including a distal element that interacts with the promoter via a chromatin loop in exhausted T cells. The 3D chromatin architecture of the 5q33.3 locus is dynamically remodeled upon T-cell activation, with increased promoter-enhancer interactions correlating with robust TIM-3 upregulation.

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of the HAVCR2 primary transcript generates multiple mRNA isoforms, although the full-length protein (isoform 1, 301 amino acids) is the predominant and functionally best-characterized form. The major splice variants include:

- **Isoform 1 (Canonical, Q8TDQ0-1)**: 301 amino acids; full-length transmembrane receptor containing the N-terminal IgV domain, mucin domain, transmembrane domain, and cytoplasmic tail.
- **Isoform 2 (Q8TDQ0-2)**: A soluble isoform generated by alternative splicing that skips exon 3 (encoding the transmembrane domain). This soluble TIM-3 (sTIM-3) is secreted into the extracellular milieu and can act as a decoy receptor, sequestering galectin-9 and other ligands, thereby antagonizing membrane-bound TIM-3 signaling. Elevated levels of sTIM-3 have been detected in the serum of cancer patients and correlate with poor prognosis.
- **Isoform 3 (Q8TDQ0-3)**: A variant lacking a portion of the mucin domain due to the use of an alternative splice acceptor site in exon 4. This isoform exhibits altered glycosylation patterns and potentially altered ligand binding affinity.

The differential expression of these isoforms is tissue-specific and dynamically regulated during T-cell differentiation. Exhausted T cells predominantly express the full-length membrane-bound isoform, whereas regulatory T cells (Tregs) show relatively higher expression of the soluble isoform, suggesting a mechanism for cell-type-specific modulation of TIM-3 signaling.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The TIM-3 protein (UniProt Q8TDQ0) is a 301-amino-acid type I transmembrane glycoprotein with a molecular weight of approximately 33.4 kDa for the unmodified polypeptide, which increases to ~55-70 kDa upon extensive N-linked glycosylation. The protein is organized into distinct structural and functional domains from the N-terminus to the C-terminus:

1. **Signal Peptide (aa 1-21)**: A hydrophobic leader sequence that directs the nascent polypeptide to the endoplasmic reticulum (ER) for co-translational translocation into the secretory pathway. This peptide is cleaved off during maturation.

2. **Immunoglobulin Variable (IgV)-like Domain (aa 22-131)**: The N-terminal extracellular domain responsible for ligand binding. This domain adopts a canonical immunoglobulin fold consisting of a two-layer beta-sandwich with nine beta-strands (A, B, C, C', C'', D, E, F, G). Critically, the IgV domain of TIM-3 contains a unique structural feature: a highly conserved metal ion-dependent adhesion site (MIDAS)-like motif, which is atypical for Ig superfamily members and is more characteristic of integrins. This motif coordinates a calcium ion that is essential for the high-affinity binding of TIM-3 to its ligands, particularly phosphatidylserine (PtdSer) exposed on apoptotic cells. The FG loop and CC' loop of the IgV domain form the primary binding interface for galectin-9 and CEACAM1.

3. **Mucin-like Domain (aa 132-202)**: A heavily O-glycosylated, proline/serine/threonine-rich (PST-rich) region that extends the IgV domain away from the cell membrane, functioning as a rigid stalk. The mucin domain is highly variable in length and glycosylation status across different TIM family members and cell types. The dense O-glycosylation protects the receptor from proteolytic cleavage and contributes to the overall extended conformation of the extracellular region, facilitating ligand engagement. Differential glycosylation of the mucin domain can also modulate the accessibility of the IgV domain to its ligands.

4. **Transmembrane Domain (aa 203-223)**: A single-pass hydrophobic alpha-helix that anchors the protein in the plasma membrane. The transmembrane domain is highly conserved and may participate in homodimerization or heterodimerization with other receptors, although the precise oligomeric state of TIM-3 in the membrane remains an area of active investigation.

5. **Cytoplasmic Tail (aa 224-301)**: The intracellular domain is relatively short (78 amino acids) but is functionally critical for signal transduction. It contains several conserved tyrosine residues and a unique binding motif for the Src homology 2 (SH2) domain-containing protein tyrosine phosphatase SHP-2 (PTPN11). The juxtamembrane region contains a conserved tyrosine (Tyr256) and a cysteine residue (Cys258) that can be palmitoylated, anchoring the receptor to lipid rafts and facilitating signalosome assembly. The C-terminal region contains a second tyrosine (Tyr263) that, upon phosphorylation, creates a docking site for the E3 ubiquitin ligase and adaptor protein BAT3 (HLA-B-associated transcript 3, also known as BAG6).

### 2.2 High-Resolution Crystal Structure

The representative high-resolution structure of the human TIM-3 IgV domain was solved by X-ray crystallography (PDB: 6NGI) at a resolution of 2.1 Å. The structure reveals the canonical IgV fold with several distinctive features:

- **The FG loop**: This extended loop (residues 100-110) protrudes from the beta-sandwich and forms a critical part of the ligand-binding surface. In the crystal structure, the FG loop adopts a conformation that creates a shallow hydrophobic groove capable of accommodating the carbohydrate recognition domain (CRD) of galectin-9.
- **The CC' loop**: This loop (residues 55-65) contains the MIDAS-like motif, with conserved aspartate and glutamate residues that coordinate a calcium ion. This metal ion is essential for PtdSer binding and is also involved in the interaction with CEACAM1.
- **Dimerization interface**: The crystal structure reveals a homodimeric assembly, with the dimer interface formed primarily by interactions between the A' strand and the G strand of adjacent monomers. This dimerization is likely physiologically relevant, as it may facilitate the clustering of TIM-3 molecules on the cell surface upon ligand engagement, thereby amplifying intracellular signaling.

### 2.3 Ligand Binding Sites and Structural Basis of Recognition

TIM-3 is a promiscuous receptor that engages multiple structurally unrelated ligands, each binding to distinct or overlapping sites on the IgV domain:

- **Galectin-9 (LGALS9)**: The principal ligand, galectin-9, is a tandem-repeat galectin with two carbohydrate recognition domains (CRDs) connected by a linker peptide. The N-terminal CRD of galectin-9 binds to the FG loop of TIM-3's IgV domain in a carbohydrate-independent manner. This interaction is unique among galectins, as most galectin-ligand interactions are glycan-dependent. The binding of galectin-9 to TIM-3 induces receptor clustering and triggers the phosphorylation of Tyr256 and Tyr263 in the cytoplasmic tail, leading to the recruitment of SHP-2 and the dissociation of BAT3, thereby initiating inhibitory signaling.
- **CEACAM1**: Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a heterophilic ligand that binds to TIM-3 via its N-terminal IgV domain. The CEACAM1-TIM-3 interaction is thought to occur in cis (on the same cell) and is required for the maturation and cell surface expression of TIM-3. This interaction is critical for the inhibitory function of TIM-3 on T cells.
- **HMGB1**: High-mobility group box 1 (HMGB1) is a nuclear DNA-binding protein that is released into the extracellular space during necrosis or by activated immune cells. TIM-3 binds to HMGB1, thereby sequestering this damage-associated molecular pattern (DAMP) molecule and preventing its interaction with Toll-like receptors (TLRs) and the receptor for advanced glycation end-products (RAGE) on dendritic cells. This mechanism suppresses the innate immune response to tumor-derived DNA and inhibits the activation of DCs.
- **Phosphatidylserine (PtdSer)**: The MIDAS-like motif in the IgV domain binds to PtdSer exposed on the surface of apoptotic cells. This interaction mediates the engulfment of apoptotic bodies by TIM-3-expressing macrophages and DCs, a process known as efferocytosis, and contributes to the maintenance of immune tolerance.

### 2.4 Post-Translational Modifications

TIM-3 is subject to extensive post-translational modifications that regulate its expression, trafficking, and signaling:

- **N-linked glycosylation**: The IgV domain contains two conserved N-glycosylation sites (Asn74 and Asn101). Glycosylation at these sites is essential for proper protein folding and cell surface expression. Altered glycosylation patterns have been observed in tumor-associated TIM-3, which can affect ligand binding affinity.
- **O-linked glycosylation**: The mucin domain is heavily O-glycosylated, with multiple sites of O-GalNAc addition on serine and threonine residues. This modification is critical for the extended conformation of the extracellular domain.
- **Palmitoylation**: Cys258 in the cytoplasmic tail is palmitoylated, which anchors TIM-3 to cholesterol-rich lipid raft microdomains. This localization is required for efficient signal transduction, as it brings TIM-3 into proximity with Src family kinases and other signaling molecules.
- **Tyrosine phosphorylation**: Upon ligand engagement, Tyr256 and Tyr263 are phosphorylated by Src family kinases (e.g., Lck, Fyn). Phosphorylated Tyr263 serves as a docking site for the SH2 domain of SHP-2, while phosphorylation of Tyr256 is required for the release of BAT3 from the cytoplasmic tail.

> **Interactive 3D Protein Visualizer: Load HAVCR2 (PDB: 6NGI)**
> [Interactive 3D Protein Visualizer: Load HAVCR2 (PDB: 6NGI)](/tools/protein-structure-viewer?source=direct&pdbId=6NGI)
> This tool allows you to explore the atomic coordinates of the TIM-3 IgV domain, visualize the FG loop and CC' loop ligand-binding surfaces, and examine the MIDAS-like motif coordinating the calcium ion.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The TIM-3 Signalosome: A Bifunctional Signaling Hub

The cytoplasmic tail of TIM-3 is devoid of intrinsic enzymatic activity and relies on the recruitment of intracellular adaptor proteins to transduce signals. Quantitative interactomics using mass spectrometry-based proteomics has revealed that TIM-3 assembles a dynamic "signalosome" whose composition is fundamentally different in resting versus ligand-engaged T cells. In resting T cells, TIM-3 is constitutively associated with the large adaptor protein BAT3 (BAG6). BAT3 binding to the cytoplasmic tail of TIM-3 is essential for maintaining the receptor in a permissive state that allows T-cell activation. BAT3 recruits the active form of the Src family kinase Lck to the TIM-3 complex, thereby promoting TCR signaling and T-cell proliferation.

Upon engagement of TIM-3 by galectin-9, a conformational change occurs in the cytoplasmic tail, leading to the phosphorylation of Tyr256 and Tyr263. This phosphorylation event triggers the dissociation of BAT3 from the TIM-3 cytoplasmic tail and the simultaneous recruitment of the SH2 domain-containing protein tyrosine phosphatase SHP-2 (PTPN11). The recruitment of SHP-2 to the TIM-3 signalosome is the central event in TIM-3-mediated inhibition. SHP-2 dephosphorylates key components of the TCR signaling cascade, including Lck, ZAP-70, and LAT, thereby attenuating TCR-proximal signaling and suppressing T-cell activation, proliferation, and cytokine production.

This "switch" mechanism—from a BAT3-associated permissive state to a SHP-2-associated inhibitory state—explains the bifunctional nature of TIM-3 as both a costimulatory and coinhibitory receptor, depending on the ligand environment and the activation state of the T cell.

### 3.2 Downstream Signaling Pathways in T Cells

The engagement of TIM-3 and the subsequent recruitment of SHP-2 lead to the inhibition of multiple downstream signaling pathways:

- **TCR signaling**: SHP-2 dephosphorylates the TCRζ chain and ZAP-70, reducing the amplitude and duration of TCR-proximal signals. This results in decreased activation of downstream effectors, including PLCγ1, PKCθ, and the Ras-MAPK pathway.
- **NF-κB pathway**: TIM-3 engagement inhibits the activation of the canonical NF-κB pathway, reducing the transcription of pro-inflammatory cytokine genes (IFNG, IL2, TNF).
- **PI3K-Akt-mTOR pathway**: TIM-3 signaling suppresses the PI3K-Akt-mTOR axis, leading to reduced cellular metabolism, decreased glycolysis, and impaired T-cell effector function. This metabolic checkpoint contributes to the bioenergetic exhaustion of chronically stimulated T cells.
- **NFAT pathway**: TIM-3 engagement inhibits the nuclear translocation of NFATc1 and NFATc2, further suppressing cytokine gene expression. The NFAT pathway is also critical for the expression of exhaustion-associated genes, including PDCD1 (PD-1), LAG3, and HAVCR2 itself, creating a positive feedback loop that reinforces the exhausted state.

### 3.3 TIM-3 in T-Cell Exhaustion

T-cell exhaustion is a state of progressive dysfunction characterized by the sustained expression of multiple inhibitory receptors (PD-1, TIM-3, LAG-3, [TIGIT](/knowledge/bioinformatics/genes/immunology-checkpoints/tigit-gene-structure-function-pathway)), loss of effector cytokine production (IL-2, TNF-α, IFN-γ), impaired cytolytic activity, and metabolic dysregulation. TIM-3 is a defining marker of the most severely exhausted T-cell populations, particularly the terminally differentiated exhausted subset (Tex-term). [Single-cell RNA sequencing](/knowledge/bioinformatics/single-cell-rna-sequencing-from-bulk-to-resolution) (scRNA-seq) studies of tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) have demonstrated that TIM-3+ CD8+ T cells represent a distinct exhausted population with high expression of TOX, ENTPD1 (CD39), and CXCL13, and low expression of the transcription factor TCF7 (TCF-1). These TIM-3+ exhausted T cells are characterized by a transcriptional program that is distinct from both effector and memory T cells, with enrichment for genes involved in negative regulation of T-cell activation and apoptosis.

The NFIL3/TIM-3 axis has been shown to regulate effector Th1 inflammation in COPD, where NFIL3 drives TIM-3 expression on Th1 cells, contributing to the chronic inflammatory state. In the tumor microenvironment, the interaction between TIM-3 on exhausted T cells and galectin-9 on tumor cells or immunosuppressive myeloid cells creates a suppressive niche that prevents effective anti-tumor immunity.

### 3.4 TIM-3 in Innate Immune Cells

Beyond its role in adaptive immunity, TIM-3 is expressed on multiple innate immune cell types, where it exerts context-dependent functions:

- **Dendritic Cells (DCs)**: TIM-3 is expressed on a subset of conventional DCs (cDCs) and plasmacytoid DCs (pDCs). In DCs, TIM-3 acts as a "sensor" for nucleic acids by binding to HMGB1. The TIM-3-HMGB1 interaction sequesters HMGB1 and prevents its binding to endosomal TLRs (TLR3, TLR7, TLR9), thereby suppressing the innate immune response to tumor-derived DNA and RNA. Ablation of TIM-3 in DCs leads to increased inflammasome activation and the production of IL-1β, which in turn promotes the expansion of stem-like CD8+ T cells with enhanced anti-tumor activity. This finding highlights the critical role of TIM-3 in regulating the "tumor immune temperature" by modulating DC function.
- **Macrophages**: TIM-3 is expressed on tumor-associated macrophages (TAMs) and M2-polarized macrophages, where it promotes an immunosuppressive phenotype. TIM-3 engagement by galectin-9 on macrophages drives the production of [IL-10](/knowledge/bioinformatics/genes/immunology-checkpoints/il10-gene-structure-function-pathway) and suppresses the production of pro-inflammatory cytokines. TIM-3 also mediates efferocytosis—the phagocytic clearance of apoptotic cells—via its binding to PtdSer. This process is critical for tissue homeostasis and the resolution of inflammation but can be co-opted by tumors to promote an immunosuppressive TME. In prostate cancer, PRDM1 drives a TIM3+ macrophage immunosuppressive niche via LGALS9 signaling, contributing to tumor progression.
- **Natural Killer (NK) Cells**: TIM-3 is expressed on activated and exhausted NK cells. In glioblastoma patients, reduced T and NK cell activity correlates with TIM-3 and BAT3 dysregulation, suggesting that TIM-3 contributes to the profound immunosuppression observed in this malignancy. TIM-3 engagement on NK cells suppresses their cytotoxic activity and cytokine production.
- **Microglia**: TIM-3 is expressed on microglia, the resident immune cells of the central nervous system. Recent studies have identified HAVCR2 as a genetic risk factor for late-onset Alzheimer's disease (AD). TIM-3 regulates microglial function and neuroinflammation, and its expression is aberrantly regulated during AD progression. TIM-3 deficiency in microglia leads to altered phagocytic activity and exacerbated neuroinflammation, implicating TIM-3 in the pathogenesis of neurodegenerative diseases.

### 3.5 Protein-Protein Interaction Networks

The TIM-3 interactome is complex and dynamic. Key protein-protein interactions include:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| LGALS9 (Galectin-9) | Extracellular ligand | Induces TIM-3 clustering, Tyr phosphorylation, SHP-2 recruitment, inhibitory signaling |
| CEACAM1 | Extracellular heterophilic ligand | Required for TIM-3 maturation and cell surface expression; mediates cis-inhibition |
| HMGB1 | Extracellular ligand | Sequesters DAMP, suppresses TLR-mediated innate immune responses in DCs |
| PtdSer | Extracellular lipid ligand | Mediates efferocytosis by macrophages and DCs |
| BAT3 (BAG6) | Cytosolic adaptor | Maintains TIM-3 in permissive state; recruits Lck; promotes T-cell activation |
| SHP-2 (PTPN11) | Cytosolic phosphatase | Dephosphorylates TCR signaling components; mediates inhibitory signaling |
| Lck | Cytosolic kinase | Phosphorylates TIM-3 cytoplasmic tail; promotes TCR signaling when bound to BAT3 |
| Fyn | Cytosolic kinase | Phosphorylates TIM-3; involved in signalosome assembly |
| SHIP1 | Cytosolic phosphatase | Recruited to TIM-3 signalosome; dephosphorylates PIP3, inhibiting Akt signaling |

### 3.6 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant T as "Tumor Cell"
    participant LG9 as "Galectin-9"
    participant TIM3 as "TIM-3 (HAVCR2)"
    participant BAT3 as "BAT3 (BAG6)"
    participant SHP2 as "SHP-2 (PTPN11)"
    participant TCR as "TCR Signaling Complex"
    participant NFAT as "NFAT Transcription Factor"
    participant IL2 as "IL-2/IFN-γ Genes"
    T->>LG9: Secretes Galectin-9
    LG9->>TIM3: Binds to IgV domain (FG loop)
    TIM3->>TIM3: Receptor clustering & Tyr256/263 phosphorylation
    TIM3->>BAT3: Dissociation of BAT3 from cytoplasmic tail
    TIM3->>SHP2: Recruitment of SHP-2 to phospho-Tyr263
    SHP2->>TCR: Dephosphorylates Lck, ZAP-70, LAT
    TCR->>NFAT: Reduced Ca2+ flux & NFAT nuclear translocation
    NFAT->>IL2: Suppressed IL-2, IFN-γ, TNF-α transcription
    Note over TIM3,SHP2: Inhibitory signalosome active
    Note over BAT3: BAT3-Lck complex disrupted
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Loss-of-Function Mutations in SPTCL and HLH

The most clinically significant pathogenic mutations in HAVCR2 are germline, biallelic loss-of-function mutations that cause a rare but severe form of subcutaneous panniculitis-like T-cell lymphoma (SPTCL) associated with hemophagocytic lymphohistiocytosis (HLH). SPTCL is a rare subtype of peripheral T-cell lymphoma characterized by CD8+ T-cell infiltration of the subcutaneous adipose tissue. The association between HAVCR2 mutations and SPTCL was first established by Gayden et al. (2018), who identified germline compound heterozygous or homozygous mutations in a significant proportion of SPTCL patients.

The two most common pathogenic missense mutations are:

- **p.Tyr82Cys (Y82C)**: This mutation is located in the IgV domain of TIM-3, within the FG loop that is critical for ligand binding. The substitution of a tyrosine with a cysteine introduces an unpaired cysteine residue that can form aberrant disulfide bonds, leading to protein misfolding and retention in the endoplasmic reticulum. This results in a significant reduction in cell surface expression of TIM-3 and loss of ligand-binding function.
- **p.Ile97Met (I97M)**: This mutation is also located in the IgV domain, in close proximity to the MIDAS-like motif. The substitution of isoleucine with methionine disrupts the hydrophobic core of the domain, destabilizing the protein fold and leading to reduced cell surface expression.

These mutations are inherited in an autosomal recessive manner, and affected individuals are either homozygous or compound heterozygous for these variants. The loss of TIM-3 function leads to uncontrolled T-cell activation and proliferation, particularly in the subcutaneous adipose tissue, resulting in the development of SPTCL. The associated HLH is a life-threatening hyperinflammatory syndrome characterized by uncontrolled activation of macrophages and cytotoxic T cells, leading to cytokine storm, cytopenias, hepatosplenomegaly, and multi-organ failure.

The clinical spectrum of HAVCR2-associated SPTCL is broad. A multicenter study of 70 SPTCL patients from the French Cutaneous Lymphoma Group found that HAVCR2 mutations were present in a substantial proportion of cases and were strongly associated with the development of HLH. Patients with biallelic HAVCR2 mutations had a more aggressive clinical course and a higher risk of HLH compared to those without mutations. A subsequent multicenter study from Thailand confirmed these findings and demonstrated that HAVCR2 mutations are a defining feature of a distinct clinico-pathological subtype of SPTCL.

### 4.2 Other Germline Mutations and Clinical Phenotypes

Beyond SPTCL, germline HAVCR2 mutations have been associated with other clinical phenotypes:

- **Recurrent Autoinflammatory Myocarditis**: Pernaa et al. (2024) described a young male patient with recurrent episodes of inflammatory myocarditis who was found to have a germline HAVCR2 mutation. This case expands the clinical spectrum of HAVCR2 deficiency to include autoinflammatory cardiac disease, highlighting the role of TIM-3 in maintaining immune homeostasis in the heart.
- **Hodgkin's Lymphoma**: A novel loss-of-function mutation in HAVCR2 was identified in a patient diagnosed with Hodgkin's lymphoma, suggesting that TIM-3 deficiency may predispose to a broader range of lymphomas.
- **EBV-positive Peripheral T-cell Lymphoma**: A compound heterozygous HAVCR2 mutation was identified in a patient with EBV-positive peripheral T-cell lymphoma (NOS) and HLH, with down-regulated TIM-3 signaling.

### 4.3 Somatic Mutations and Expression Alterations in Cancer

In addition to germline mutations, somatic alterations in HAVCR2 expression and signaling are common in the tumor microenvironment. While somatic mutations in the HAVCR2 coding sequence are relatively rare in most solid tumors, epigenetic silencing and post-transcriptional regulation play a major role in modulating TIM-3 expression. DNA methylation of the HAVCR2 promoter has been observed in several cancer types, including melanoma, where it correlates with reduced TIM-3 mRNA expression. Conversely, in many tumors, TIM-3 is overexpressed on tumor-infiltrating immune cells, contributing to the immunosuppressive TME.

Pan-cancer analyses have revealed that HAVCR2 expression is significantly upregulated in multiple tumor types, including lung adenocarcinoma (LUAD), hepatocellular carcinoma (HCC), gastric cancer, ovarian cancer, and melanoma. High TIM-3 expression on TILs is generally associated with poor prognosis and resistance to PD-1/PD-L1 blockade, making it a rational target for combination immunotherapy.

### 4.4 Regulatory Polymorphisms and Disease Susceptibility

Several single nucleotide polymorphisms (SNPs) in the HAVCR2 gene have been associated with altered disease susceptibility:

- **rs4704846 (A/G)**: This SNP is located in the 3' UTR of HAVCR2 and modulates susceptibility to HIV-1 infection. The G allele is associated with reduced TIM-3 expression and increased resistance to HIV-1 acquisition, likely due to enhanced T-cell effector function.
- **rs13360222 (C/T)**: This SNP is located in an enhancer element upstream of the HAVCR2 promoter. The minor T allele decreases enhancer activity in human macrophages, leading to reduced HAVCR2 expression.
- **rs1036199 (A/C)**: This SNP is associated with altered risk of tuberculosis, with the C allele conferring protection against Mycobacterium tuberculosis infection.
- **rs10053538 (C/T)**: This SNP has been associated with differential risk of lung adenocarcinoma and squamous cell carcinoma, with the effect being subtype-specific.

### 4.5 Clinical Differentials and Diagnostic Considerations

The diagnosis of HAVCR2-associated SPTCL should be considered in patients presenting with subcutaneous nodules, particularly in the extremities and trunk, accompanied by systemic symptoms such as fever, cytopenias, and elevated ferritin levels suggestive of HLH. The histopathological hallmark is a lobular panniculitis with atypical CD8+ T cells rimming individual adipocytes. Genetic testing for HAVCR2 mutations is essential for confirming the diagnosis and distinguishing this entity from other forms of panniculitis and cutaneous T-cell lymphomas.

The differential diagnosis includes:
- **Lupus erythematosus panniculitis**: A benign inflammatory condition that can mimic SPTCL clinically and histologically.
- **Primary cutaneous γδ T-cell lymphoma**: A more aggressive lymphoma with a different immunophenotype (CD4-, CD8-, γδ TCR+).
- **Other peripheral T-cell lymphomas**: Including mycosis fungoides with panniculitic involvement.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 TIM-3 in Chronic Viral Infections

TIM-3 plays a critical role in the immune response to chronic viral infections, where it contributes to the exhaustion of virus-specific T cells. In chronic infections such as HIV, HBV, and HCV, the sustained expression of TIM-3 on virus-specific CD8+ T cells is associated with impaired cytokine production and cytolytic function. The interaction between TIM-3 and galectin-9, which is upregulated on infected cells and immune cells during chronic inflammation, drives the exhaustion of antiviral T cells, allowing the virus to persist.

The regulatory polymorphism rs4704846 in the HAVCR2 3' UTR modulates susceptibility to HIV-1 infection, with the G allele associated with reduced TIM-3 expression and enhanced T-cell function. This finding suggests that genetic variation in HAVCR2 can influence the outcome of HIV-1 exposure and infection.

### 5.2 Epstein-Barr Virus (EBV) and TIM-3

EBV is a ubiquitous herpesvirus that establishes lifelong latency in B cells and is associated with several malignancies, including Burkitt lymphoma (BL), Hodgkin lymphoma, and nasopharyngeal carcinoma. The interaction between EBV and the immune system is complex, and TIM-3 plays a role in modulating the antiviral immune response.

In EBV-positive Burkitt lymphoma, tumor-infiltrating CD8+ T cells have been characterized as quiescent rather than exhausted, with low expression of TIM-3 and other exhaustion markers. This quiescent state may contribute to the "cold" immune microenvironment of BL and the poor response to immunotherapy. Conversely, in EBV-positive peripheral T-cell lymphoma, HAVCR2 mutations leading to TIM-3 deficiency have been associated with HLH, suggesting that loss of TIM-3 function can lead to uncontrolled T-cell activation in the context of EBV infection.

### 5.3 SARS-CoV-2 and TIM-3

During the COVID-19 pandemic, TIM-3 was identified as a potential biomarker of severe disease. Patients with severe COVID-19 exhibit elevated TIM-3 expression on T cells and NK cells, correlating with T-cell exhaustion and impaired antiviral immunity. The dysregulation of TIM-3 signaling may contribute to the profound lymphopenia and immune dysfunction observed in severe cases.

### 5.4 Bacterial Infections and TIM-3

TIM-3 has been implicated in the immune response to

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)